Schwartz D, Mendonca M, Schwartz I, Xia Y, Satriano J, Wilson C B, Blantz R C
Division of Nephrology & Hypertension, University of California, San Diego, San Diego, California 92110, USA.
J Clin Invest. 1997 Jul 15;100(2):439-48. doi: 10.1172/JCI119551.
Excess NO generation plays a major role in the hypotension and systemic vasodilatation characteristic of sepsis. Yet the kidney response to sepsis is characterized by vasoconstriction resulting in renal dysfunction. We have examined the roles of inducible nitric oxide synthase (iNOS) and endothelial NOS (eNOS) on the renal effects of lipopolysaccharide administration by comparing the effects of specific iNOS inhibition, -N6-(1-iminoethyl)lysine (L-NIL), and 2,4-diamino6-hydroxy-pyrimidine vs. nonspecific NOS inhibitors (nitro- -arginine-methylester). cGMP responses to carbamylcholine (CCh) (stimulated, basal) and sodium nitroprusside in isolated glomeruli were used as indices of eNOS and guanylate cyclase (GC) activity, respectively. LPS significantly decreased blood pressure and GFR (112+/-4 vs. 83+/-4 mmHg; 2.66+/-0.29 vs. 0. 96+/-0.22 ml/min, P < 0.05) and inhibited the cGMP response to CCh. GC activity was reciprocally increased. L-NIL and 2, 4-diamino-6-hydroxy-pyrimidine administration prevented the decrease in GFR (2.71+/-0.28 and 3.16+/-0.18 ml/min, respectively), restored the normal response to CCh, and GC activity was normalized. In vitro application of L-NIL also restored CCh responses in LPS glomeruli. Neuronal NOS inhibitors verified that CCh responses reflected eNOS activity. L-NAME, a nonspecific inhibitor, worsened GFR (0.41+/-0.15 ml/min), a reduction that was functional and not related to glomerular thrombosis, and eliminated the CCh response. No differences were observed in eNOS mRNA expression among the experimental groups. Selective iNOS inhibition prevents reductions in GFR, whereas nonselective inhibition of NOS further decreases GFR. These findings suggest that the decrease in GFR after LPS is due to local inhibition of eNOS by iNOS, possibly via NO autoinhibition.
过量的一氧化氮(NO)生成在脓毒症的低血压和全身血管舒张中起主要作用。然而,肾脏对脓毒症的反应以血管收缩为特征,进而导致肾功能障碍。我们通过比较特异性诱导型一氧化氮合酶(iNOS)抑制剂-N6-(1-亚氨基乙基)赖氨酸(L-NIL)和2,4-二氨基-6-羟基嘧啶与非特异性一氧化氮合酶(NOS)抑制剂(硝基-L-精氨酸甲酯)对脂多糖给药后肾脏效应的影响,研究了iNOS和内皮型一氧化氮合酶(eNOS)的作用。分别将分离肾小球中对氨甲酰胆碱(CCh)(刺激的、基础的)和硝普钠的环磷酸鸟苷(cGMP)反应用作eNOS和鸟苷酸环化酶(GC)活性的指标。脂多糖显著降低血压和肾小球滤过率(GFR)(分别为112±4与83±4 mmHg;2.66±0.29与0.96±0.22 ml/min,P<0.05),并抑制对CCh的cGMP反应。GC活性则相应增加。给予L-NIL和2,4-二氨基-6-羟基嘧啶可防止GFR降低(分别为2.71±0.28和3.16±0.18 ml/min),恢复对CCh的正常反应,且GC活性恢复正常。在体外应用L-NIL也可恢复脂多糖处理的肾小球中对CCh的反应。神经元型一氧化氮合酶抑制剂证实对CCh的反应反映了eNOS活性。非特异性抑制剂L-NAME使GFR恶化(0.41±0.15 ml/min),这种降低是功能性的,与肾小球血栓形成无关,并消除了对CCh的反应。各实验组之间eNOS mRNA表达未观察到差异。选择性抑制iNOS可防止GFR降低,而非选择性抑制NOS则进一步降低GFR。这些发现表明,脂多糖处理后GFR降低是由于iNOS对eNOS的局部抑制,可能是通过NO自身抑制作用。